View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 24, 2018

PanOptica doses first patient in Phase l/ll trial of PAN-90806

PanOptica has dosed the first patient in a Phase l/ll clinical trial evaluating PAN-90806 as monotherapy for the treatment of neovascular eye diseases.

PanOptica has dosed the first patient in a Phase l/ll clinical trial evaluating PAN-90806 as monotherapy for the treatment of neovascular eye diseases.

The dose-ranging trial intends to enrol 60 newly diagnosed patients with neovascular age-related macular degeneration (wet AMD) at various sites in the US and the European Union (EU).

As part of the trial, patients will be randomised to one of three dose strengths of PAN-90806.

The trial aims to demonstrate tolerability, a broader safe dose range, as well as a more robust response rate and effect size in treatment-naïve patients with wet AMD.

The masked trial is scheduled to be conducted for up to three months.

“The trial aims to demonstrate tolerability, a broader safe dose range, as well as a more robust response rate and effect size in treatment-naïve patients with wet AMD.”

Last month, PanOptica filed an investigational new drug application (IND) amendment in the US, and clinical trial applications (CTAs) to enable the trial.

PanOptica President and CEO Paul Chaney said: “This Phase l/ll trial builds on research completed to date and advances PAN-90806 as a potentially safe and effective topical eye drop treatment for back-of-the-eye diseases such as wet AMD and diabetic retinopathy.

“Our new formulation of PAN-90806 has the potential to improve upon the safety and tolerability seen in our previous Phase l study in patients with wet AMD and may enhance the response rate and treatment effect across a higher, broader dose-range.”

PAN-90806 is a selective inhibitor of vascular endothelial growth factor (VEGF) receptor signalling.

The VEGF protein plays a critical role in angiogenesis, the formation of new blood vessels; and increased permeability, leakage from blood vessels; the two pathological processes that contribute to the vision loss associated with wet AMD.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU